$TECH
Bio-Techne Corporation
Life sciences company providing proteins, antibodies, and diagnostics for research.
TECH key facts as of November 14, 2026
- Latest AI research report
- TECH Stock Analysis: Growth, Valuation and Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Hold (0 Strong Buy, 0 Buy, 12 Hold, 1 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $71.67 mean (range $65.00 to $73.00) (as of November 20, 2026)
- Sector
- Healthcare
Analysis from Nov 14, 2026
TECH Stock Analysis: Growth, Valuation and Risks
Bio-Techne’s shares closed near their 52-week high as analysts weighed recent operating results and progress on a Merck KGaA merger deal. Growth and liquidity are positive, but earnings trends, premium valuation, and price targets below the close leave the outlook mixed.
Previous Reports
TECH FAQ
What is StockAlpha's latest view on TECH?
StockAlpha's latest AI research report on Bio-Techne Corporation (TECH), "TECH Stock Analysis: Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Bio-Techne’s shares closed near their 52-week high as analysts weighed recent operating results and progress on a Merck KGaA merger deal. Growth and liquidity are positive, but earnings trends, premium valuation, and price targets below the close leave the outlook mixed.
When was the TECH research last updated?
The most recent TECH report was published on November 14, 2026.
What do analysts expect for TECH?
As of November 1, 2026, the analyst consensus on TECH is Hold (0 Strong Buy, 0 Buy, 12 Hold, 1 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $71.67 mean (range $65.00 to $73.00).
Is this TECH research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Bio-Techne into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Bio-Techne's peers: Today's sector-level news and moves around the stock